Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 4/20 | 0.45 |
| ▸ | TPSD1 | Q9BZJ3 | 3/20 | 0.45 |
| ▸ | TPSG1 | Q9NRR2 | 3/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 9/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | F2R | P25116 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17471119 | 0.87 | EPHX2 (0.42) | TPSAB1TPSD1TPSG1GNAI3GNAO1 | |
| SCHEMBL19884753 | 0.85 | TPSAB1 (0.46) | TPSAB1TPSD1TPSG1CHRM4GNAI3 | |
| SCHEMBL17471129 | 0.83 | HDAC2 (0.42) | CYP2D6KCNH2HRH3 | |
| SCHEMBL7447536 | 0.82 | TPSAB1 (0.46) | TPSAB1TPSD1TPSG1CHRM4ITGB3 | |
| SCHEMBL17471820 | 0.80 | CYP2C19 (0.50) | CYP2D6KCNH2HRH3 | |
| SCHEMBL13225898 | 0.77 | KMT2A (0.62) | CYP2D6KCNH2HRH3 | |
| SCHEMBL17471132 | 0.77 | NAMPT (0.43) | TPSAB1TPSD1TPSG1CYP2D6KCNH2 | |
| SCHEMBL17471120 | 0.76 | EPHX2 (0.55) | CYP2D6KCNH2HRH3 | |
| SCHEMBL25570284 | 0.76 | GNAI3 (0.48) | TPSAB1TPSD1TPSG1GNAI3GNAO1 | |
| SCHEMBL17471822 | 0.75 | LMNA (0.43) | TPSAB1TPSD1TPSG1CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580415-B2 | Compounds | PROXIMAGEN LIMITED (GB) | 2017-02-28 | — | — | US | disclosed |
| US-9580415-B2 | Compounds | PROXIMAGEN LIMITED (GB) | 2017-02-28 | — | — | US | disclosed |
| US-20160024080-A1 | NEW COMPOUNDS | PROXIMAGEN, LLC | 2016-01-28 | — | — | US | disclosed |
| US-20160024080-A1 | NEW COMPOUNDS | PROXIMAGEN, LLC | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024080-A1 | NEW COMPOUNDS | QSOX1, MAOB, MAOA | TPSAB1 27/4885TPSD1 79/4885TPSG1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.